Spots Global Cancer Trial Database for stage iii pancreatic cancer ajcc v6 and v7

Every month we try and update this database with for stage iii pancreatic cancer ajcc v6 and v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy	NCT02381561	Advanced Bile D... Stage II Esopha... Stage II Pancre... Stage IIA Esoph... Stage IIA Pancr... Stage IIB Esoph... Stage IIB Pancr... Stage III Colon... Stage III Esoph... Stage III Gastr... Stage III Liver... Stage III Pancr... Stage III Recta... Stage III Small... Stage IIIA Colo... Stage IIIA Esop... Stage IIIA Gast... Stage IIIA Rect... Stage IIIA Smal... Stage IIIB Colo... Stage IIIB Esop... Stage IIIB Gast... Stage IIIB Rect... Stage IIIB Smal... Stage IIIC Colo... Stage IIIC Esop... Stage IIIC Gast... Stage IIIC Rect... Stage IV Colon ... Stage IV Esopha... Stage IV Gastri... Stage IV Liver ... Stage IV Pancre... Stage IV Rectal... Stage IV Small ... Stage IVA Colon... Stage IVA Liver... Stage IVA Recta... Stage IVB Colon... Stage IVB Liver... Stage IVB Recta...	Intensity-Modul... Laboratory Biom... Pharmacological... Ropidoxuridine	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery	NCT02336087	Pancreatic Aden... Unresectable Pa... Stage III Pancr... Stage IV Pancre...	Gemcitabine Hyd... Paclitaxel Albu... Metformin Hydro... Therapeutic Die... Laboratory Biom... Quality-of-Life...	18 Years -	City of Hope Medical Center
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer	NCT02451553	Advanced Malign... Bile Duct Carci... Recurrent Malig... Recurrent Pancr... Stage III Pancr... Stage IVA Pancr... Stage IVB Pancr...	Afatinib Dimale... Capecitabine Laboratory Biom...	19 Years -	University of Washington
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer	NCT03257761	Extrahepatic Bi... Gallbladder Ade... Metastatic Panc... Recurrent Chola... Recurrent Gallb... Recurrent Hepat... Recurrent Intra... Recurrent Pancr... Stage III Gallb... Stage III Hepat... Stage III Intra... Stage III Pancr... Stage IIIA Gall... Stage IIIA Hepa... Stage IIIB Gall... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Gallbl... Stage IV Hepato... Stage IV Pancre... Stage IVA Gallb... Stage IVA Hepat... Stage IVA Intra... Stage IVB Gallb... Stage IVB Hepat... Stage IVB Intra... Unresectable Ga... Unresectable Pa...	Durvalumab Guadecitabine	18 Years -	University of Southern California
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery	NCT02194829	Metastatic Panc... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	AZD1775 Gemcitabine Nab-paclitaxel	18 Years -	National Cancer Institute (NCI)
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	NCT02498613	Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr...	18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy	NCT02381561	Advanced Bile D... Stage II Esopha... Stage II Pancre... Stage IIA Esoph... Stage IIA Pancr... Stage IIB Esoph... Stage IIB Pancr... Stage III Colon... Stage III Esoph... Stage III Gastr... Stage III Liver... Stage III Pancr... Stage III Recta... Stage III Small... Stage IIIA Colo... Stage IIIA Esop... Stage IIIA Gast... Stage IIIA Rect... Stage IIIA Smal... Stage IIIB Colo... Stage IIIB Esop... Stage IIIB Gast... Stage IIIB Rect... Stage IIIB Smal... Stage IIIC Colo... Stage IIIC Esop... Stage IIIC Gast... Stage IIIC Rect... Stage IV Colon ... Stage IV Esopha... Stage IV Gastri... Stage IV Liver ... Stage IV Pancre... Stage IV Rectal... Stage IV Small ... Stage IVA Colon... Stage IVA Liver... Stage IVA Recta... Stage IVB Colon... Stage IVB Liver... Stage IVB Recta...	Intensity-Modul... Laboratory Biom... Pharmacological... Ropidoxuridine	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery	NCT00669734	Locally Advance... Pancreatic Acin... Pancreatic Duct... Stage III Pancr... Stage IV Pancre...	Falimarev Inalimarev Laboratory Biom... Sargramostim	18 Years -	National Cancer Institute (NCI)
Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations	NCT03040986	KRAS NP_004976.... Stage III Pancr... Stage IV Pancre...	Laboratory Biom... Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery	NCT00288093	Pancreatic Aden... Stage III Pancr...	3-Dimensional C... Triapine	18 Years -	National Cancer Institute (NCI)
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery	NCT01783171	Pancreatic Aden... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	Akt Inhibitor M... Dinaciclib Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	NCT02498613	Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr...	18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery	NCT01660971	Metastatic Panc... Recurrent Pancr... Stage III Pancr... Stage IV Pancre...	Dasatinib Erlotinib Hydro... Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer	NCT03073785	Pancreatic Aden... Recurrent Pancr... Stage I Pancrea... Stage IA Pancre... Stage IB Pancre... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre...	Capecitabine Fluorouracil Laboratory Biom... Pharmacological... Stereotactic Bo... Zoledronic Acid	19 Years -	University of Nebraska
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection	NCT05334069	Acute Lymphobla... Acute Myeloid L... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Chronic Lymphoc... Chronic Myeloid... Gastroesophagea... Head and Neck C... Hematopoietic a... Invasive Breast... Kidney Carcinom... Malignant Hepat... Malignant Solid... Melanoma Muscle-Invasive... RISS Stage I Pl... RISS Stage II P... RISS Stage III ... Sarcoma Stage I Bladder... Stage I Breast ... Stage I Colorec... Stage I Esophag... Stage I Gastric... Stage I Lung Ca... Stage I Ovarian... Stage I Pancrea... Stage I Prostat... Stage I Uterine... Stage II Bladde... Stage II Breast... Stage II Colore... Stage II Esopha... Stage II Gastri... Stage II Lung C... Stage II Ovaria... Stage II Pancre... Stage II Prosta... Stage II Uterin... Stage III Bladd... Stage III Breas... Stage III Color... Stage III Esoph... Stage III Gastr... Stage III Lung ... Stage III Ovari... Stage III Pancr... Stage III Prost... Stage III Uteri... Stage IV Bladde... Stage IV Breast... Stage IV Colore... Stage IV Esopha... Stage IV Gastri... Stage IV Lung C... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Uterin... Thyroid Gland C...	Questionnaire A... Biospecimen Col...	40 Years - 75 Years	Alliance for Clinical Trials in Oncology
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery	NCT02194829	Metastatic Panc... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	AZD1775 Gemcitabine Nab-paclitaxel	18 Years -	National Cancer Institute (NCI)
Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations	NCT03040986	KRAS NP_004976.... Stage III Pancr... Stage IV Pancre...	Laboratory Biom... Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: